title: Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease.
abstract: Amyloidogenic processing of the amyloid precursor protein (APP) with deposition in brain of the 42 amino acid long amyloid beta-peptide (A beta(42)) is considered central to Alzheimer's disease (AD) pathology. However, it is generally believed that nonfibrillar pre-amyloid A beta(42) deposits have to mature in the presence of A beta(40) into fibrillar amyloid plaques to cause neurodegeneration. Here, we describe an aggressive form of AD caused by a novel missense mutation in APP (T714I) directly involving gamma-secretase cleavages of APP. The mutation had the most drastic effect on A beta(42)/A beta(40) ratio in vitro of approximately 11-fold, simultaneously increasing A beta(42) and decreasing A beta(40) secretion, as measured by matrix-assisted laser disorption ionization time-of-flight mass spectrometry. This coincided in brain with deposition of abundant and predominant nonfibrillar pre-amyloid plaques composed primarily of N-truncated A beta(42) in complete absence of A beta(40). These data indicate that N-truncated A beta(42) as diffuse nonfibrillar plaques has an essential but undermined role in AD pathology. Importantly, inhibiting secretion of full-length A beta(42 )by therapeutic targeting of APP processing should not result in secretion of an equally toxic N-truncated A beta(42).
authors.affiliation: Laboratory of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Born-Bunge Foundation, University of Antwerp, Universiteitsplein 1, B-2610, Antwerpen, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Kumar-Singh
authors.forename: C
authors.initials: C
authors.lastname: De Jonghe
authors.forename: M
authors.initials: M
authors.lastname: Cruts
authors.forename: R
authors.initials: R
authors.lastname: Kleinert
authors.forename: R
authors.initials: R
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Mercken
authors.forename: B
authors.initials: B
authors.lastname: De Strooper
authors.forename: H
authors.initials: H
authors.lastname: Vanderstichele
authors.forename: A
authors.initials: A
authors.lastname: Löfgren
authors.forename: I
authors.initials: I
authors.lastname: Vanderhoeven
authors.forename: H
authors.initials: H
authors.lastname: Backhovens
authors.forename: E
authors.initials: E
authors.lastname: Vanmechelen
authors.forename: P M
authors.initials: PM
authors.lastname: Kroisel
authors.forename: C
authors.initials: C
authors.lastname: Van Broeckhoven
mesh_terms: D000544:Alzheimer Disease / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019943:Amino Acid Substitution / Q000235:genetics; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism*; D016282:Aspartic Acid Endopeptidases; D002460:Cell Line; D010450:Endopeptidases / Q000235:genetics / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020125:Mutation, Missense / Q000235:genetics*; D010375:Pedigree; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism*; D058225:Plaque, Amyloid / Q000737:chemistry / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D011499:Protein Processing, Post-Translational; D012995:Solubility; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014162:Transfection
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human